PAVM PAVmed Inc.
Surgical & Medical Instruments & Apparatus · Nasdaq · SEC CIK 1624326 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY410.3%
TTM net income YoY-693.3%
TTM EPS YoY—
Revenue 3-yr CAGR-54.7%
Net income 3-yr CAGR—
Margins
Gross margin-212.2%
Operating margin-19,315.5%
Net margin-12,406.8%
FCF margin-3,024.3%
EBITDA margin-19,264.2%
Returns
ROE-61.2%
ROA-50.1%
ROIC (approx.)-84.8%
Asset turnover0.00x
Leverage & solvency
Liabilities / assets71.2%
Debt / equity0.00x
Current ratio0.41x
Interest coverage-5,717.40x
Cash quality & payout
Operating cash flow / net income0.24x
Accruals ratio-38.1%
Payout ratio—
Capex / revenue38.5%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $71,000 | $3.00M | $2.45M | $377,000 | $500,000 |
| Cost of revenue | $218,000 | $4.84M | $6.42M | $3.61M | $585,000 |
| Gross profit | -$147,000 | -$1.84M | -$3.97M | -$3.24M | -$85,000 |
| R&D expense | $4.49M | $5.93M | $14.28M | $25.34M | $19.85M |
| SG&A expense | $16.25M | $24.52M | $30.95M | $41.41M | $25.42M |
| Operating income | -$21.81M | -$44.49M | -$68.80M | -$91.09M | -$54.39M |
| Interest expense | $21,000 | $45,000 | $589,000 | $1.28M | — |
| Pretax income | -$2.47M | $28.43M | -$79.26M | -$103.24M | -$56.13M |
| Income tax | $0 | $0 | — | — | — |
| Net income | $401,000 | $39.79M | -$64.17M | -$88.98M | -$50.35M |
| EBITDA | -$21.70M | -$43.29M | -$65.86M | -$88.63M | -$54.17M |
| EPS (basic) | -5.63 | 99.15 | -9.16 | -15.03 | -0.65 |
| EPS (diluted) | -5.63 | 14.90 | -9.16 | -15.03 | -0.65 |
| Weighted avg. shares (diluted) | 670,466 | 2.17M | 7.23M | 5.94M | 77.52M |
| Balance sheet | |||||
| Cash & equivalents | $1.24M | $1.19M | $19.64M | $39.74M | $77.26M |
| Receivables | $15,000 | $18,000 | $61,000 | $17,000 | $200,000 |
| Inventory | — | — | $278,000 | $111,000 | — |
| Current assets | $2.26M | $2.16M | $24.50M | $43.93M | $82.64M |
| PP&E, net | $77,000 | $151,000 | $1.78M | $2.45M | $1.58M |
| Intangibles | — | — | $1.42M | $3.44M | $2.03M |
| Total assets | $38.81M | $30.66M | $33.12M | $53.98M | $86.98M |
| Current liabilities | $14.84M | $35.45M | $54.18M | $41.20M | $7.56M |
| Total liabilities | $16.51M | $37.69M | $57.14M | $43.05M | $7.56M |
| Shareholders' equity | $33.97M | -$2.50M | -$53.83M | -$9.68M | $61.67M |
| Shares outstanding | 927,934 | 373,300 | 8.58M | 6.30M | 86.37M |
| Cash flow statement | |||||
| Operating cash flow | -$5.21M | -$33.55M | -$52.04M | -$70.98M | -$40.59M |
| Capital expenditure | $31,000 | $55,000 | $242,000 | $1.54M | $1.47M |
| Free cash flow | -$5.24M | -$33.61M | -$52.28M | -$72.53M | -$42.06M |
| Investing cash flow | -$31,000 | -$16.18M | $758,000 | -$4.74M | -$3.72M |
| Financing cash flow | $5.59M | $31.28M | $31.17M | $38.21M | $104.31M |
| Depreciation & amortization | $105,000 | $1.20M | $2.93M | $2.46M | $226,000 |
| Stock-based compensation | $1.71M | $6.45M | $11.14M | $19.53M | $15.01M |
Free plan shows the latest 5 periods; Pro shows all 11 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.